Hyderabad, Nov 14 (PTI) Dr. ReddyÂ’s Laboratories Ltdtoday announced today that it has launched ClofarabineInjection, a therapeutic equivalent generic version of Clolar(clofarabine) Injection in the United States market, followingthe approval from the US Food and Drug Administration (USFDA).
According to a statement issued by the city-based drugmaker, its generic version of the injection is available insingle-dose, 20 ml flint vials containing 20 mg of clofarabinein 20 ml of solution (1mg/mL).
The Clolar brand and its generic had U.S. sales ofapproximately USD 53 million MAT (Moving Annual Total) for themost recent twelve months ended in September 2017, accordingto IMS Health. Clolar is a registered trademark of GenzymeCorporation, it said.
Clofarabine Injection is used to treat acuteLymphoblastic Leukemia, a cancer of white blood cells.
Dr Reddy's shares are trading at Rs 2338.80 apiece onBSE at 1430 hrs. PTI GDKNRB.
This is unedited, unformatted feed from the Press Trust of India wire.